In order to reduce the risk of coronary heart disease and regeneration of the body, it is worth to use the Biofiton Healthy Vessels supplement.
Phytotablets Biofiton Healthy Vessels contain vegetable raw materials whose operation is focused on:

1. STANDARDIZATION OF BLOOD PRESSURE. Biologically active substances contained in hawthorn flowers, birch leaves and horsetail herb improve the functioning of the heart and regulate blood pressure.
2. STANDARDIZATION OF BLOOD CIRCULATION. Hawthorn blossom, Melilot herb, chestnut seeds, horsetail herb and buckwheat flower have a mild vasodilatory effect and improve cerebral, cardiac and peripheral blood circulation.
3. STANDARDIZATION OF CHOLESTEROL LEVEL. The biologically active substances contained in the bark of the buckthorn and the peppermint leaf prevent the formation of fat deposits on the walls of blood vessels and maintain the appropriate level of cholesterol in the blood.
4. GAIN AND PURIFYING. Common periwinke herb and melilot, dog rose fruit and cowberry leaves clean blood vessels from various types of deposits, they regulate the elasticity and elasticity of these vessels
5. NORMALIZATION OF TRANSFER OF MATTER. Hawthorn blossom, chestnut seeds, dog rose and buckwheat flower activate metabolic processes, enabling the supply of nutrients to all cells of the body and thereby normalizing blood flow.

Ischemic heart disease – ( Latin Morbus ischaemicus cordis, MIC; ischaemic heart disease (IHD)) – a set of disease symptoms resulting from a chronic insufficient condition of myocardial cells supplying oxygen and nutrients. Disturbance of the balance between the demand and the possibility of their delivery, despite the use of autoregulatory mechanisms that increase the flow of the myocardium, called the coronary reserve, leads to hypoxia, also known as coronary insufficiency.
As a consequence, it often leads to angina, as well as myocardial infarction. Coronary heart disease with all its subtypes is the most common cause of death in most Western countries. The most common cause of ischemic disease is coronary atherosclerosis.

EPIDEMIOLOGY
Results, among others POL-MONICA research project, which is part of the WHO Worldwide coordinated WHO MONICA Project, showed a close correlation between the development of ischemic heart disease and the presence of risk factors for this disease. These studies, conducted on large populations, have shown a steady increase in the incidence of ischemic heart disease in Poland. For Poland, the incidence is on average 620 cases per 100,000 for men and 220 cases per 100,000 for women. The incidence is lower in the villages than in big cities. The incidence of angina increases rapidly with age in both sexes: from 0.1-1% in women aged 45-54 to 10-15% in women aged 65-74 and from 2-5% in men aged 45 –54 years to 10–20% in men aged 65–74. In Poland, an increase in the incidence of this disease among women and young people is also observed: an increased incidence among 20- and 30-year-olds.

PATHOGENESIS
In more than 90% of cases, coronary atherosclerosis (atherosclerotic plaque) is responsible for the disease, leading to their narrowing and thus coronary flow impairment. For this reason, the term coronary artery disease is synonymous with ischemic disease. In other cases, however, other mechanisms (sometimes called non-convulsive) are responsible for the mechanism of ischemia:
• Anemia
• hypotension or hypovolemia
• respiratory failure
• hyperthyroidism
heart defects, especially narrowing of the aortic valve
• cardiomyopathies, especially hypertrophic
hypertension.
There are also rare coronary artery disease with a background other than atherosclerotic, which causes insufficient blood circulation and thus myocardial ischemia:
inflammatory changes of the coronary vessels in the course of inflammatory diseases of the vessels (Vasculitis)
– rheumatic disease
rheumatoid arthritis
– nodular polyarteritis
– systemic lupus erythematosus
– syphilis
– Takayasu’s disease
– sepsis
congenital metabolic disorders
– Fabry disease
– Hurler team
– amyloidosis
– cystinuria
Post-traumatic changes in the coronary arteries (eg after coronarography)
congenital anomalies of the coronary arteries (hypoplasia of the arteries or one coronary artery, arteriovenous fistulas, departure of the coronary artery from the pulmonary trunk – Bland-White-Garland syndrome)
– aortic dissecting aneurysm, including coronary arteries
– oppression of the coronary arteries from the outside, for example by a growing tumor
– congenital or acquired coronary artery aneurysms (eg Kawasaki’s disease)
so-called muscle bridges, i.e. muscle fibers located over the artery, which may shrink in the artery: stenosis associated with muscle bridges over the coronary arteries.
Coronary artery spasm giving a picture of ischemic heart disease can also occur with Prinzmetal’s angina and after stopping nitrate intake.

Coronary circulation
In the initial section of the aorta, just above the petals of the aortic valve, two coronary arteries depart from it (at a place called Valsalva Bay)
 left coronary artery begins with the trunk of the left coronary artery (PLTW), more often referred to as Anglo-Saxon denomination, as LMCA (left main coronary artery). After 2–30 millimeters, PLTW is divided into:
• front interventricular branch – GMP (left anterior descending)
• branching around – GO (CX – circumflex)
• in 37% of cases there are three branches – the so-called intermediate branch
 right coronary artery (RCA).
The most important coronary artery is LAD, called the artery of life. It supplies a significant portion of the free wall of the heart and the septum, and its closure causes extensive myocardial infarction and often sudden cardiac death. The human heart weighs about 300 grams (it is assumed to be 0.4% of body weight), and within a minute about 250 ml of blood flows through it (4% of circulating blood volume); the heart consumes 11% of the oxygen consumed by the human body. This circulation may increase approximately 4-5 times (coronary reserve).

STAGES OF NEGECTIVE HEART MENS FAULTS
In response to the momentary ischemia and the subsequent return of circulation (reperfusion), there is the phenomenon of ischaemic preconditioning, i.e. toughening of the muscle by ischaemia, which consists in maintaining for 1-2 hours after the incident of ischemia increased tolerance for possible subsequent ischemia. It is currently considered the most effective heart defense mechanism against the effects of ischemia. Unfortunately, this mechanism is effective in the case of short-term ischemia. In cases of long (a dozen or so minutes) persistence of ischaemia, the so-called stunned myocardium develops, i.e. the phenomenon of mechanical impairment of the heart lasting up to several weeks. This mechanism works mainly in response to acute ischemia. In cases of chronic ischemia, a condition called hibernating myocardium appears, which is potentially reversible after reperfusion, but it develops disorders such as dyskinesia, hypokinesis or akinesis of the ischemic segment of the myocardium. Ischemia lasting more than 20 minutes leads to the development of necrosis known as myocardial infarction.

GROUNDING HOLES
In the case of stable angina, there are 3 compartments of coronary artery stenoses that are important for the disease picture:
• Insignificant stenosis – arterial lumen reduced by <50%, cross-sectional area reduced by <75%. Atherosclerotic plaque in stable state does not cause symptoms; the coronary reserve and resting coronary flow remain unchanged.
• Significant stenosis – arterial lumen diameter reduced by 50% -80%, cross-sectional area reduced by 75% -90%. The coronary reserve is reduced and therefore physical exercise may produce symptoms of angina.
• Critical stenosis – arterial lumen diameter reduced by> 80%, cross-sectional area decreased by> 90%. Symptoms of angina are already at rest.

RISK FACTORS
The POL-MONICA studies determined the risk factors for coronary heart disease:
• social factors
level of education
type of employment (position, type of work, physical activity at work, stress related to
job)
income
marital status
household structure
level of social support and satisfaction with social contacts
• behavioral factors
personality type A
smoking
alcohol consumption
way and type of nutrition
level of physical activity
sleep disorders
• somatic risk factors
hypertension
hypercholesterolaemia
abdominal obesity
diabetes.

The Polish Cardiac Society considers that the most important risk factors are:
Lifestyle:
• smoking
• a diet rich in calories and animal fats
• physiological and biochemical factors
• elevated cholesterol, especially LDL
• elevated triglyceride levels
• hyperglycemia or diabetes
• hyperhomocysteinemia
• increased levels of thrombogenic (thrombogenic) factors, e.g. fibrinogen.

Lifestyle and biochemical factors are considered modifiable factors. PTK considers as not subject to modification:
• age over 45 years for men and 55 years for women
• premature menopause
• disease of other arteries (lower limbs, brain) on the atherosclerotic background.

Postulated risk factors
Risk factors are discussed below, which in numerous studies have an effect on the course of ischemic disease, but have not received official recommendations as to how to proceed if they are found.
• Myeloperoxidase – MPO – an enzyme from the peroxidase group that occurs in granulocyte granules and is involved in inflammatory reactions. A 49% increase in the risk of cardiovascular disease, including ischemic heart disease, has been demonstrated in population studies in people with high levels of this enzyme. Currently, it is believed that an elevated level of MPO is associated with the risk of so-called unstable atherosclerotic plaque, the formation of which usually precedes the occurrence of an acute coronary event. Cholesterol-packed atherosclerotic plaque eventually leads to an inflammatory process. This leads to an influx of granulocytes to the site of inflammation and release of enzymes, including proteases and MPO. This can lead to loosening of the structure of the atherosclerotic plaque, which leads to its instability and eventually detachment of the embolic material. Work is currently underway on drugs that will act as an MPO inhibitor, which is likely to be more effective in preventing coronary events than statins. However, as long as these drugs are not introduced, an increased level of MPO may only indicate an increased coronary risk, and the only possible therapeutic decision will be to increase the pressure to reduce other risk factors.
• C-reactive protein (CRP) – is another indicator of inflammation, the increase of which correlates with the risk of heart attack. Studies have been carried out in the light of which an increase in CRP is associated with a threefold increase in the risk of myocardial infarction. However, this did not lead to accepted recommendations for people with ischemic disease and an increased risk of CRP. The studies have shown that statins can lower the level of CRP (the so-called pleiotropic effect of their action). In the 1990s, high hopes were also associated with selective COX-2 inhibitors, which due to their selective activity were supposed to inhibit inflammation, the presence of which is associated with an increase in the level of CRP. However, when using one of them, rofecoxib, even increased cardiac mortality associated with its use was found. At present, certain hopes are associated with the substance bisphosphinohexane, which is an inhibitor of CRP protein. To date, it has been shown to be effective in vitro and in animal models, where inhibition of myocardial destruction was found in the case of experimentally induced infarction. It should also be remembered that ultra-sensitive tests that are not routinely performed in laboratories are necessary to assess CRP levels.
• Infectious factors in the pathogenesis of atherosclerosis. The role of infectious agents in the development of atherosclerosis and ischemic heart disease, especially infections with pathogens such as Chlamydia pneumoniae, cytomegalovirus, Herpes simplex, Helicobacter pylori, is postulated. Increased mortality due to ischemic heart disease has been observed in people with active Chlamydia pneumoniae infection (elevated levels of immunoglobulin A). Subsequently, in the WIZARD and AZACS studies, the effectiveness of the azithromycin antibiotic treatment was not confirmed, as the results obtained were not statistically significant. The involvement of other infectious agents in the pathogenesis of atherosclerosis has not been confirmed, although research on this background is still ongoing.

MODIFICATION OF RISK FACTORS
As part of the prevention of coronary heart disease, as many factors as possible should be limited. As part of broadly understood prevention of ischemic disease, social and individual goals can be distinguished.

Social goals
They are based on changes in habits and habits relevant to the development of the disease and widely present in the given society. In Poland, the following main recommendations are particularly important:

• promoting healthy eating and physical activity
• fight against smoking and excessive alcohol consumption.

Dietary recommendations:

• reduction of fat intake below 35% of the total daily energy dose, including energy from saturated fatty acids below 10%, avoiding trans fats
• cholesterol intake below 300 milligrams per day
• starch as an energy source over 50% of daily demand
• reduction of simple carbohydrate intake (glucose)
• lowering sodium consumption below 6 grams per day
• increasing the consumption of fiber, cereal products, including bread
• increasing the consumption of natural antioxidant vitamins, i.e. high consumption of vegetables and fruits
• increasing the consumption of fish as a source of protein, and reducing the consumption of fatty meats, especially pork.

Individual goals
• Smoking cessation. Tobacco smoke, regardless of its source (pipe, cigar, cigarette) is considered a risk factor for atherosclerosis. Passive smoking is also a risk factor.
• Lowering LDL cholesterol in primary prevention below 130 milligrams / dl, in secondary prevention below 100 milligrams / dl (according to the latest indications even below 70 mg / dl in people after coronary artery procedures and in people with diabetes).
• Elevation of HDL cholesterol above 35 mg / dl in men and 40 mg / dl in women. There are currently no effective drugs that increase HDL levels. Work on torcetrapib has been discontinued, while apolipoprotein A-I Milano is undergoing clinical trials. Fibrates and estrogens may be used to some extent.
• Adequate blood pressure control – optimal values ​​120/80 mm Hg.
• Adequate control of blood glucose levels by appropriate measures in case of diabetes or other glucose tolerance disorders.
• Limiting alcohol consumption. Alcohol intake of more than 70-80 g per day increases the risk of cardiac death. Moderate consumption of alcohol (in the amount of 1-2 standard doses of alcohol), especially in the form of red wine (due to the content of polyphenols) has a beneficial effect.
• Increased physical activity that reduces LDL cholesterol and increases HDL.
• Lowering triglyceride levels below 150 mg / dL.
• Treatment of overweight or obesity to restore optimal BMI in the range of 20-25 kg / m².

SYMPTOMS
The first symptom of ischemic heart disease may be sudden cardiac arrest and in the absence of effective resuscitation sudden cardiac death. Numerous observations indicate that sudden cardiac deaths occur statistically most frequently on Mondays between 7 and 9 am.
A characteristic symptom of chronic ischemic disease is chest pain, which is characterized by high variability and is often atypical, but has some distinguishing features:
• It is localized in a sternum, has a stabbing character, radiates to the shoulders, especially the left, medial parts of the arms and forearms or fingers IV and V. It can also radiate to the jaw, jaw or neck, but also to the epigastrium.
• Has a tightening, constricting, choking effect, usually combined with a feeling of shortness of breath (hence angina pectoris), expanding, stinging or referred to as a feeling of weight in the chest. Sometimes it is accompanied by sweats, anxiety, fear and fainting.
• It intensifies during exercise, stress, under the influence of cold, after a heavy meal.
• It goes away on its own at rest or under the influence of sublingual use of nitroglycerin.

When the pain persists at rest or after administration of nitroglycerin, there is a serious suspicion of an acute coronary syndrome, which requires different treatment !.
The so-called functional classification of angina pectoris according to the Canadian Society of Cardiology is important, which describes the severity of the disease

DIAGNOSTICS
Diagnosis of ischemic heart disease is based on intelligence and non-invasive and invasive cardiology research. As a supplement, it is also necessary to perform laboratory tests, mainly aimed at detecting co-existing risk factors. and therefore determines further treatment of the patient.
Non-invasive cardiovascular examinations
• 12-lead resting ecstasy, treated as a preliminary test, because even in people with severe forms of ischemic heart disease may be normal
• Exercise ECG – exercise test – due to the availability and low price of the test of choice in the diagnosis of ischemic heart disease. It is characterized by high sensitivity (68%) and specificity (77%).
• Image load tests:
exercise perfusion scintigraphy
Dobutamine stress echocardiography
stress echocardiography with a vasodilator (dipyridamole).
• Evaluation of coronary calcification rate (currently not recommended in routine diagnostic procedure).
• Outpatient Holter ECG monitoring is currently not recommended as a routine method, but may reveal cases of silent ischaemia.
Invasive methods of cardiovascular examination
• coronography
In the course of coronary angiography, a special situation may arise where, in a person with a characteristic history of angina and a positive exercise test, coronary angiography will not show changes in coronary arteries. This situation (positive interview and exercise test with negative coronary angiography) is called the cardiological syndrome X (as opposed to metabolic syndrome X). Currently, it is believed that the cause of the X syndrome are changes in the microcirculation, while the coronary arteries remain unobstructed. The prognosis for life for this syndrome is good, but it significantly worsens the quality of life.

TREATMENT
The goal of treating chronic, stable ischemic disease is to improve the quality of life by reducing the number of ischemic attacks and improving prognosis. This goal is achieved through the use of the following drugs:

• antiplatelet drugs:
acetylsalicylic acid at a dose of 75-150 mg daily for life
ticlopidine should not be currently used due to the risk of neutropenia and thrombocytopenia
clopidogrel should be used in selected situations. The CAPRIE study (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) showed its higher effectiveness compared to aspirin in patients with peripheral vascular disease, stroke and myocardial infarction, however, these results are not statistically significant and the difference in price does not justify routine use of clopidogrel.
• lipid-lowering drugs:

Many studies have shown a slowdown in atherosclerosis progression when using statin drugs. A beneficial effect has been reported regardless of the formulation used, but the strongest effect has been demonstrated with atorvastatin. Other statin drugs that may be used in lipid-lowering therapy are pravastatin, simvastatin, and lovastatin.

• beta-blockers are effective especially in the treatment of coronary heart disease in people after myocardial infarction, as they reduce mortality by 30% in this group. The use of cardioselective beta-blocker without its own internal activity is recommended. These criteria meet:
Bisoprolol – It is taken orally and its bioavailability is 90%. By blocking the β-adrenergic receptors, it contributes to reducing the impact of the sympathetic nervous system and, consequently, to reducing the frequency of cardiac contractions. Due to the balance of lipo- and hydrophilicity, bisoprolol exhibits the advantages of both lipophilic beta-blockers (as well as high absorption) and hydrophilic beta-blockers (e.g. long half-life) while avoiding the disadvantages of belonging to the extreme elements of these groups. Significant improvements in left ventricular systolic function, as well as overall well-being and exercise tolerance have been found in patients using the original bisoprolol (i.e., dimethicon in the envelope). A reduction in the number of hospitalizations due to worsening heart failure has also been reported
atenolol – It is taken orally. By affecting the adrenergic system, atenolol slows down the heart rhythm by reducing the heart’s oxygen demand.
metoprolol – It is taken orally. It reduces the strength and frequency of heart contractions. Reduces or stops the properties of catecholamines that are released during physical activity or stress.
and carvedilol not belonging to this group.
Calcium channel blockers or calcium channel blockers (also known as calcium channel blockers) – only those that slow the heart rate, i.e. verapamil-like medicines, can be used. Nifedipine derivatives increase the risk of death.
• Angiotensin converting enzyme inhibitors (for example, perindopril, lisinopril) should be used in the presence of hypertension or signs of circulatory failure. They must also be absolutely used in people with coronary heart disease after a myocardial infarction, because, as numerous studies have shown (HOPE, EUROPA), this is associated with a reduction in mortality in those using it.
• Nitrates, or nitroglycerine derivatives, appear in medicine as a short and long-acting form.
Short-lived nitrates are used to stop the angina attack and should only be used for this purpose. It is a medication that everyone with ischemic disease should always have with him and should take it sublingually in case of pain that does not disappear spontaneously or after rest. Due to their rapid action, these drugs cause a drop in blood pressure and should be taken in a sitting position.
Long-acting nitriles should only be used in cases where the use of the above drugs does not control the symptoms of the disease. Their use improves disease control, but their effects have not been shown to improve prognosis. Additionally, during their use there is a phenomenon of tolerance, that is, to maintain the potency, the dose of the drug should be increased. This is partially prevented by the use of long-acting nitrates with a sufficiently long break, at least several hours. For this reason, they are used in modified-release forms once a day, or up to twice daily, in the morning and at noon with an evening-night break.
• Trimetazidine registered in Poland as Preductal (for use 3 times a day), Preductal MR (for use 2 x daily), Trimetaratio or Metazidine, belongs to drugs with metabolic and cytoprotective activity. It works by improving the use of energy in ischemic conditions, in other words it imitates the phenomenon of ischemic quenching. It is registered for the treatment of ischemic heart disease from 1997. Its equivalent in the American market is ranolazine
Drugs that may be used in the treatment of PDO, but are not currently in the recommendations of medical societies
• Ivabradine – Unlike currently used drugs, the mechanism of action of ivabradine is different and consists in the selective blocking function of the sinus node f channel. This causes the release of resting depolarization, which is manifested by the release of the sinus rhythm at rest and effort. Slowing the heart rate reduces the myocardial demand per se, reducing the heart’s need for oxygen, while by increasing the time the heart stays in diastole (when the heart muscle is nourished), it improves blood flow through the heart muscle, i.e. its perfusion. In 2005, it was approved as a preparation for Procoralan for the alternative treatment of patients with stable coronary artery disease with normal sinus rhythm in whom there are contraindications to the use of beta-blockers.
• Nicorandil – develops its action by activating the potassium channel sarcolemmas and cell membranes of myocardial cells. This medicine
is used in stable coronary disease to prevent acute coronary events. In the case of long-term use, tolerance may develop (it becomes necessary to use higher and higher doses).
• Ezetimibe – a cholesterol-lowering medicine, registered in Poland in 2006. Due to the mechanism of action different from statins, it can be used together with them, which increases the level of cholesterol lowering.
• Sartans – drugs with a similar effect to converting enzyme inhibitors, lacking some side effects. Currently, high hopes are associated with the simultaneous use of sartans together with converting enzyme inhibitors (the so-called double blockade of the renin-angiotensin-aldosterone system) in the treatment of hypertension, heart failure and diabetic nephropathy, while the place of sartans in the treatment of ischemic disease has not yet been established.

Special situations during treatment
At the turn of the 20th and 21st centuries, 1473 cases of serious side effects were described, of which 522 were fatal in patients with coronary heart disease using sildenafil (Viagra). Death occurred due to cardiovascular causes 4-5 hours after taking Viagra. After careful research, the use of Viagra together with nitrates has been banned since 2001.
Rehabilitation in coronary heart disease
Physical rehabilitation reduces mortality from coronary heart disease, reduces the number of hospitalizations and improves quality of life.

INVASIVE TREATMENT OF HEART HEART DISEASE

Ischemic heart disease occurs in two forms: chronic (stable) and acute (unstable), today falling under the concept of acute coronary syndrome. One form can change into another, because they differ only in dynamics (in the chronic form, there is a narrowing of the coronary artery lumen, in the unstable form, the lumen of the vessel suddenly closes due to a blood clot or the existence of the so-called unstable atherosclerotic plaque). This conditions a different course of proceedings in these cases. Acute coronary syndromes, depending on the occurrence of changes in blood biochemical tests suggesting myocardial infarction (necrosis), such as glycogen phosphorylase, cardiac fatty acid binding protein (h-FABP), myoglobin, troponin, creatine kinase, and ECG changes involving on the evaluation of elevation or non-elevation of the ST segment of the electrocardiogram, were divided into:

• STEMI – (ST Elevation Myocardial Infarction) – acute coronary syndrome with ST segment elevation corresponding to myocardial infarction (ST segment elevation, markers of myocardial necrosis present).
• NSTE ACS – (No ST Elevation Acute Coronary Syndrome), corresponding to the old concept of unstable coronary artery disease, which depending on the presence of necrosis markers are divided into:
UA (Unstable Angina) – unstable coronary artery disease in which, despite the characteristic clinical manifestations of myocardial ischaemia, there are no electrocardiographic changes or an increase in myocardial necrosis indices.
NSTEMI (No ST Elevation Myocardial Infarction) – myocardial infarction without ST segment elevation, corresponding to the previously used concepts of subendocardial infarction or myocardial infarction without Q wave, in which biochemical markers of the presence of myocardial necrosis appear, but there is no characteristic for acute myocardial infarction, ST elevation.

Depending on the syndrome, the following procedures can be used to treat:
• Thrombolytic therapy – based on the administration of thrombolytic drugs to dissolve the clot and restore proper blood circulation. The thrombolytic agents used are streptokinase, urokinase, tissue plasminogen activator, prourokinase, recombinant tissue plasminogen activator or others.
• Invasive procedures:
percutaneous transluminal coronary angioplasty (PTCA)
coronary artery bypass grafting (CABG)
Currently, and especially in the light of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) study presented at the Congress of the American Society of Cardiology in New Orleans in March 2007, there were no differences in the incidence of death, myocardial infarction or other serious cardiovascular events in groups patients treated conservatively (in an adequate way) and patients undergoing invasive treatment.
Angio-systolic angina pectoris
Angina systolic angina – otherwise known as Prinzmetal angina (Latin variant angina) – is ischemia of the fragment of the heart muscle caused by coronary artery spasm. Unlike other types of coronary heart disease, it often occurs at rest and does not increase with exertion. It can occur in young people without the features of atherosclerosis. The result of ECG may suggest myocardial infarction due to the characteristic arcuate elevation of the ST segments. Ischemic symptoms usually disappear spontaneously or after administration of nitroglycerin. Medicines from the group of calcium channel antagonists (e.g. nifedipine, verapamil, diltiazem) are used in the treatment. The use of beta-blockers is contraindicated, as blocking beta-adrenergic receptors may increase arterial spasm.
Asymptomatic ischemic heart disease (so-called silent ischemia)
This form of ischemic heart disease (Silent angina) is characterized by the absence of coronary pain, which is the basic symptom that allows suspicion and diagnosis of ischemic heart disease. During the tests, results are clearly evidenced by ischemia (e.g. ST segment depression in a 24-hour Holter ECG). This secretive course of the disease often causes the first symptom of the disease in these patients there is sudden cardiac death.

This type of disorder often occurs (estimated at over 20%) of people with diabetes due to autonomic neuropathy.

PREVENTION
In order to prevent coronary heart disease and regeneration of the body, it is worth to use a Biofiton Healthy Vessels supplement. Phytotablets Biofiton Healthy Vessels contain vegetable raw materials whose operation is focused on:

1. STANDARDIZATION OF BLOOD PRESSURE. Biologically active substances contained in hawthorn flowers, birch leaves and horsetail herb improve the functioning of the heart and regulate blood pressure.

2. STANDARDIZATION OF BLOOD CIRCULATION. Hawthorn blossom, sweet clover herb, chestnut seeds, horsetail herb and buckwheat flower have a mild vasodilatory effect and improve cerebral, cardiac and peripheral blood circulation.

3. STANDARDIZATION OF CHOLESTEROL LEVEL. Biologically active substances contained in the buckthorn bark and peppermint leaf prevent the formation of fat deposits on the walls of blood vessels and maintain an adequate level of cholesterol in the blood.

4. STRENGTHENING AND CLEANING. Periwinkle and sweet clover herb, rosehip and lingonberry leaves cleanse blood vessels from various types of deposits, regulate the elasticity and elasticity of these vessels

5. NORMALIZATION OF MATTER CHANGE. Hawthorn blossom, horse chestnut seeds, rose hips and buckwheat flower activate metabolic processes, enabling the delivery of nutrients to all cells of the body and thus normalizing blood flow.